25 July 2024 - Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials.
Sun Pharmaceutical today announced that the US FDA approved Leqselvi (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.